NCT04964050View on ClinicalTrials.gov

A Bioequivalence Study Between Capozide Versus ACE-Hemmer-ratiopharm in Healthy Adult Participants Under Fasting Conditions

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 21, 2022

Primary Completion Date

May 26, 2022

Study Completion Date

May 26, 2022

Conditions
Healthy Volunteers
Interventions
DRUG

Capozide

Capozide will be administered as per the treatment sequence.

DRUG

ACE-Hemmer-Ratiopharm

ACE-Hemmer-Ratiopharm will be administered as per the treatment sequence.

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT04964050 - A Bioequivalence Study Between Capozide Versus ACE-Hemmer-ratiopharm in Healthy Adult Participants Under Fasting Conditions | Biotech Hunter | Biotech Hunter